BioSpace News Archive

OnQuality Pharmaceuticals today announced it presented preclinical data on OQL025 and OQL06x, at the American Association for Cancer Research (AACR) annual meeting. The conference is being held in Orlando, FL, April 14-19, 2023.

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May.

Autobahn Therapeutics today announced that it has initiated the multiple ascending dose (MAD) portion of its Phase 1 study of ABX-002 in healthy subjects.

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research.

ImCheck Therapeutics announced today data from its ongoing Phase I/IIa clinical trial EVICTION-2 at the American Association for Cancer Research (AACR) Annual Meeting 2023 in a poster presentation (CT179) titled: “First-in-Human Study of ICT01, an Anti-BTN3A Activating Monoclonal Antibody in Combination with Low Dose IL-2 in Patients with Advanced Solid Tumors (EVICTION-2 Study)”.

EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced the presentation of the first data highlighting the company’s proprietary CRISPR-Cas9 T cell exhaustion screening platform.

Immuneering Corporation announced positive initial pharmacokinetic (PK), pharmacodynamic (PD) and safety data from the Phase 1 trial of IMM-1-104 (NCT05585320), which are being shared today in a poster presentation titled “Humanized 3D tumor models that are mutationally aligned with AACR GENIE patients predict IMM-1-104 activity in RAS-addicted tumors” (abstract #4265) at the American Association for Cancer Research (AACR) annual meeting.

Bloomage Biotech, an international pioneer in biotechnology and biomaterials, demonstrated its industry leadership with its cutting-edge bioactive ingredients at the 2023 International Consumer Products Expo held in Haikou from April 10th to 15th.

Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 solution.

Serenus.AI launches the first patented autonomous clinically objective, Generative AI, case-by-case review system to improve the utilization and prior-authorization processes before medical procedures.